Amylyx Pharmaceuticals, Inc. (AMLX): who owns it and who trades it
As of Nov 16, 2026, AMLX insiders reported 38 open-market sales worth $17.2M and 2 purchases worth $152K in the last 12 months, with 46% of the sale value made under pre-set 10b5-1 plans. The largest seller was Joshua B Cohen (CEO), with $6.6M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Amylyx Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AMLX
207 funds and institutions reported AMLX shares worth $2.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 16.73M | 15.04% | $300M | +1% |
| BlackRock, Inc. | 8.83M | 7.94% | $159M | No change |
| Perceptive Advisors LLC | 8.33M | 7.50% | $150M | +1% |
| TCG Crossover Management, LLC | 6.24M | 5.62% | $112M | No change |
| Commodore Capital LP | 5.65M | 5.08% | $101M | No change |
| Jupiter Topco LLC | 5.24M | 4.71% | $94M | – |
| Saturn V Capital Management LP | 4.62M | 4.16% | $83M | +6% |
| Vanguard Capital Management LLC | 4.22M | 3.80% | $75.9M | +2% |
| Morgan Stanley | 3.13M | 2.82% | $56.2M | +44% |
| Driehaus Capital Management LLC | 3.04M | 2.73% | $54.5M | +2% |
| First Light Asset Management, LLC | 3.02M | 2.72% | $54.3M | -5% |
| Franklin Resources Inc | 2.95M | 2.65% | $53M | +30% |
| Goldman Sachs Group Inc | 2.86M | 2.57% | $51.3M | +9% |
| State Street Corp | 2.60M | 2.34% | $46.8M | +10% |
| Geode Capital Management, LLC | 2.34M | 2.10% | $41.9M | +6% |
| Adage Capital Partners Gp, L.l.c. | 1.90M | 1.71% | $34.1M | -47% |
| JPMorgan Chase & Co | 1.86M | 1.68% | $34.9M | – |
| Siren, L.L.C. | 1.48M | 1.33% | $26.6M | +20% |
| Eventide Asset Management, LLC | 1.33M | 1.19% | $23.8M | -12% |
| 683 Capital Management, LLC | 1.28M | 1.15% | $23M | -16% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AMLX insiders reported $152K of open-market purchases and $17.2M of sales. 46% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | James M Frates | CFO | Sale plan | 12,800 | $30.32 | $388K | Form 4 |
| Nov 10, 2026 | James M Frates | CFO | Sale plan | 7,200 | $30.97 | $223K | Form 4 |
| Nov 9, 2026 | Joshua B Cohen | CEO | Sale plan | 38,105 | $29.39 | $1.1M | Form 4 |
| Nov 9, 2026 | Joshua B Cohen | CEO | Sale plan | 61,895 | $30.11 | $1.9M | Form 4 |
| Nov 9, 2026 | Justin B. Klee | CEO | Sale plan | 37,483 | $29.39 | $1.1M | Form 4 |
| Nov 9, 2026 | Justin B. Klee | CEO | Sale plan | 62,517 | $30.11 | $1.9M | Form 4 |
| Nov 9, 2026 | James M Frates | CFO | Sale plan | 7,700 | $29.39 | $226K | Form 4 |
| Nov 9, 2026 | James M Frates | CFO | Sale plan | 12,300 | $30.11 | $370K | Form 4 |
| Oct 5, 2026 | George M Milne Jr | Director | Sale plan | 30,000 | $27.70 | $831K | Form 4 |
| Sep 10, 2026 | Camille L Bedrosian | Chief Medical Officer | Sale | 7,947 | $32.21 | $256K | Form 4 |
| Sep 10, 2026 | Camille L Bedrosian | Chief Medical Officer | Sale | 2,081 | $33.09 | $68.9K | Form 4 |
| Sep 10, 2026 | James M Frates | CFO | Sale | 9,768 | $32.27 | $315K | Form 4 |
| Sep 10, 2026 | James M Frates | CFO | Sale | 1,042 | $33.23 | $34.6K | Form 4 |
| Sep 10, 2026 | Gina Mazzariello | Chief Legal Officer | Sale | 9,525 | $32.46 | $309K | Form 4 |
| Sep 10, 2026 | Gina Mazzariello | Chief Legal Officer | Sale | 11 | $33.34 | $367 | Form 4 |
| Sep 10, 2026 | Joshua B Cohen | CEO | Sale | 919 | $33.15 | $30.5K | Form 4 |
| Sep 10, 2026 | Joshua B Cohen | CEO | Sale | 29,545 | $32.16 | $950K | Form 4 |
| Sep 10, 2026 | Justin B. Klee | CEO | Sale | 1,439 | $33.16 | $47.7K | Form 4 |
| Sep 10, 2026 | Justin B. Klee | CEO | Sale | 29,025 | $32.13 | $933K | Form 4 |
| Jul 10, 2026 | Gina Mazzariello | Chief Legal Officer | Sale | 15,000 | $17.61 | $264K | Form 4 |
| Jul 9, 2026 | Gina Mazzariello | Chief Legal Officer | Sale | 15,000 | $18.32 | $275K | Form 4 |
| May 21, 2026 | Karen Firestone | Director | Purchase | 3,800 | $13.51 | $51.3K | Form 4 |
| Mar 2, 2026 | Justin B. Klee | CEO | Sale | 29,282 | $14.47 | $424K | Form 4 |
| Mar 2, 2026 | Joshua B Cohen | CEO | Sale | 29,282 | $14.48 | $424K | Form 4 |
| Mar 2, 2026 | Camille L Bedrosian | Chief Medical Officer | Sale | 6,461 | $14.58 | $94.2K | Form 4 |
| Mar 2, 2026 | James M Frates | CFO | Sale | 7,909 | $14.52 | $115K | Form 4 |
| Mar 2, 2026 | Gina Mazzariello | Chief Legal Officer | Sale | 6,844 | $14.52 | $99.4K | Form 4 |
| Feb 23, 2026 | Gina Mazzariello | Chief Legal Officer | Sale | 3,419 | $14.14 | $48.3K | Form 4 |
| Feb 2, 2026 | James M Frates | CFO | Sale | 3,557 | $14.65 | $52.1K | Form 4 |
| Feb 2, 2026 | Joshua B Cohen | CEO | Sale | 15,500 | $14.68 | $228K | Form 4 |
| Feb 2, 2026 | Gina Mazzariello | Chief Legal Officer | Sale | 3,448 | $14.65 | $50.5K | Form 4 |
| Feb 2, 2026 | Justin B. Klee | CEO | Sale | 15,500 | $14.69 | $228K | Form 4 |
| Jan 16, 2026 | Joshua B Cohen | CEO | Sale | 1,974 | $13.83 | $27.3K | Form 4 |
| Jan 16, 2026 | Justin B. Klee | CEO | Sale | 1,995 | $13.89 | $27.7K | Form 4 |
| Jan 15, 2026 | Joshua B Cohen | CEO | Sale | 136,193 | $13.59 | $1.9M | Form 4 |
| Jan 15, 2026 | Justin B. Klee | CEO | Sale | 136,193 | $13.58 | $1.8M | Form 4 |
| Jan 6, 2026 | James M Frates | CFO | Sale | 3,326 | $11.11 | $37K | Form 4 |
| Jan 6, 2026 | Joshua B Cohen | CEO | Sale | 7,715 | $11.09 | $85.6K | Form 4 |
| Dec 23, 2025 | Karen Firestone | Director | Purchase | 8,100 | $12.45 | $101K | Form 4 |
| Dec 1, 2025 | Camille L Bedrosian | Chief Medical Officer | Sale | 6,580 | $14.35 | $94.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Joshua B Cohen | Co-Chief Executive Officer, Director | – | $6.6M | Nov 9, 2026 |
| Justin B. Klee | Co-Chief Executive Officer, Director | – | $6.5M | Nov 9, 2026 |
| James M Frates | Chief Financial Officer | – | $1.8M | Nov 10, 2026 |
| Gina Mazzariello | Chief Legal Officer | – | $1M | Sep 10, 2026 |
| George M Milne Jr | Director | – | $831K | Oct 5, 2026 |
| Camille L Bedrosian | Chief Medical Officer | – | $513K | Sep 10, 2026 |
| Karen Firestone | Director | $152K | – | May 21, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AMLX short interest
Moderate short interest. 10.0% of AMLX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 12%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12.82M AMLX shares were sold short, 10.0% of the shares outstanding, down 3.2% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 10.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12.82M | 9.97% | -3% | 1.22M | 10.5 |
| Oct 15, 2026 | 13.25M | 11.89% | +5% | 1.33M | 9.9 |
| Sep 30, 2026 | 12.67M | 11.37% | -6% | 1.38M | 9.2 |
| Sep 15, 2026 | 13.51M | 12.13% | +6% | 1.56M | 8.6 |
| Aug 31, 2026 | 12.74M | 11.43% | -5% | 5.38M | 2.4 |
| Aug 14, 2026 | 13.43M | 12.05% | +0% | 1.88M | 7.1 |
| Jul 31, 2026 | 13.40M | 12.03% | +9% | 1.96M | 6.8 |
| Jul 15, 2026 | 12.27M | 11.03% | -15% | 1.33M | 9.2 |
| Jun 30, 2026 | 14.39M | 12.94% | +10% | 2.04M | 7.1 |
| Jun 15, 2026 | 13.12M | 11.80% | -12% | 1.62M | 8.1 |
| May 29, 2026 | 14.96M | 13.45% | +3% | 916,139 | 16.3 |
| May 15, 2026 | 14.51M | 13.05% | -2% | 1.19M | 12.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Amylyx Pharmaceuticals company events
Amylyx Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 8, 2026AgreementAmylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc. and on September 1, 2026, the Company entered into a term sheet with Polypeptide Group AG, pursuant to which Bachem and Polypeptide, respectively, will manufacture and supply the Company’s… Filing
- Aug 20, 2026AgreementAmylyx Pharmaceuticals, Inc. entered into an underwriting agreement with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC, as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 14,090,000… Filing
- Aug 18, 2026AnnouncementAmylyx Pharmaceuticals, Inc. hosted a conference call with investors and analysts to discuss positive topline results from the LUCIDITY Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. Filing
- Aug 18, 2026AnnouncementThe Company announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 receptor antagonist, in… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 24, 2026AnnouncementShared information with investors. Filing
- Mar 3, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementAmylyx Pharmaceuticals, Inc. announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Amylyx Pharmaceuticals financials
Famous investors that hold AMLX
4 of the 50 well-known investors we track reported holding AMLX in their latest 13F filing. The largest position is Ken Griffin's, worth $14.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 488,571 | $14.2M | 0.0% | +173% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 388,699 | $11.3M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 191,689 | $5.6M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 72,935 | $2.1M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AMLX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 8.2% |
| Nov 16, 2026 | Commodore Capital LP | 13G/A | 1.6% |
| Nov 16, 2026 | Commodore Capital LP | 13G/A | 1.6% |
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 8.2% |
Questions about Amylyx Pharmaceuticals, Inc. (AMLX) stock
Who owns the most AMLX stock?
The largest reported owner of Amylyx Pharmaceuticals, Inc. (AMLX) is FMR LLC (Fidelity), with 15.0% of the company. In total, 207 funds and institutions reported holding AMLX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are AMLX insiders buying or selling?
In the last 12 months, AMLX insiders reported 2 open-market purchases worth $152K and 38 sales worth $17.2M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in AMLX?
As of Oct 30, 2026, 12.82M AMLX shares were sold short, 10.0% of the shares outstanding, down 3.2% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 10.5 trading days (days to cover). See the history.
Which famous investors hold AMLX?
4 of the 50 well-known investors we track reported AMLX in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $14.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.